Current stage in inflammatory bowel disease: What is next?. [revisión]
Por: Gómez Gómez, Gonzalo Jesús [Aparato Digestivo]
| Masedo González, Ángeles [Aparato Digestivo] | Yela San Bernardino, Carmen [Aparato Digestivo] | Martínez Montiel, Pilar [Aparato Digestivo] | Casís Herce, Begoña [Aparato Digestivo].
Colaborador(es): Servicio de Medicina del Aparato Digestivo.
Tipo de material: 
ArtículoEditor: World journal of gastroenterology, 2015Descripción: 21(40):11282-303.Recursos en línea: Acceso libre Resumen: In recent years, the incidence of inflammatory bowel disease (IBD) has been on the rise, extending to countries where it was infrequent in the past. As a result, the gap between high and low incidence countries is decreasing. The disease, therefore, has an important economic impact on the healthcare system. Advances in recent years in pharmacogenetics and clinical pharmacology have allowed for the development of treatment strategies adjusted to the patient profile. Concurrently, new drugs aimed at inflammatory targets have been developed that may expand future treatment options. This review examines advances in the optimization of existing drug treatments and the development of novel treatment options for IBD.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Revisión
|
PC16901 (Navegar estantería) | Disponible |
Formato Vancouver:
Gómez Gómez GJ, Masedo Á, Yela C, Martínez Montiel Mdel P, Casís B. Current stage in inflammatory bowel disease: What is next?. World J Gastroenterol. 2015 Oct 28;21(40):11282-303.
PMID: 26525013
PMC4616205
Contiene 212 referencias
In recent years, the incidence of inflammatory bowel disease (IBD) has been on the rise, extending to countries where it was infrequent in the past. As a result, the gap between high and low incidence countries is decreasing. The disease, therefore, has an important economic impact on the healthcare system. Advances in recent years in pharmacogenetics and clinical pharmacology have allowed for the development of treatment strategies adjusted to the patient profile. Concurrently, new drugs aimed at inflammatory targets have been developed that may expand future treatment options. This review examines advances in the optimization of existing drug treatments and the development of novel treatment options for IBD.
No hay comentarios para este ejemplar.